Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | IL2 | P60568 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6849179 | 0.76 | PTGS1 (0.47) | PTGS1PTGS2FOLH1TTRIL2 | |
| SCHEMBL12948000 | 0.72 | MAPT (0.44) | — | |
| Succinic Acid SCHEMBL23234379 | 0.71 | PTGS1 (0.42) | PTGS1PTGS2 | |
| SCHEMBL19154068 | 0.70 | TSHR (0.34) | TTRIL2 | |
| SCHEMBL29211788 | 0.69 | TTR (0.45) | TTRIL2 | |
| SCHEMBL17899835 | 0.69 | SMN1; SMN2 (0.39) | FOLH1TTRIL2 | |
| SCHEMBL24353048 | 0.69 | ACACB (0.38) | — | |
| SCHEMBL20496782 | 0.69 | TTR (0.37) | PTGS1PTGS2TTRIL2 | |
| SCHEMBL11990336 | 0.68 | LMNA (0.42) | — | |
| SCHEMBL444454 | 0.68 | LMNA (0.34) | TTRIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10436786-B2 | Methods for detecting truncated receptors using antibody-based arrays | Société des Produits Nestlé S.A. (CH) | 2019-10-08 | — | — | US | disclosed |
| US-20160123984-A1 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS | NESTEC S.A. (CH) | 2016-05-05 | — | — | US | disclosed |
| US-9274116-B2 | Drug selection for breast cancer therapy using antibody-based arrays | NESTEC S.A. (CH) | 2016-03-01 | — | — | US | disclosed |
| EP-2602623-B1 | MEHTOD FOR THE DETECTION OF INTRACELLULAR TRUNCATED RECEPTORS | NESTEC SA (CH) | 2015-09-16 | — | — | EP | disclosed |
| EP-2618146-B1 | Drug selection for breast cancer therapy using antibody-based arrays | NESTEC SA (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-20140349865-A1 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS | NESTEC S.A. (CH) | 2014-11-27 | — | — | US | disclosed |
| US-8609349-B2 | Drug selection for breast cancer therapy using antibody-based arrays | NESTEC S.A. (CH) | 2013-12-17 | — | — | US | disclosed |
| US-8535639-B2 | Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-09-17 | — | — | US | disclosed |
| EP-2618146-A2 | Drug selection for breast cancer therapy using antibody-based arrays | Nestec S.A. (CH) | 2013-07-24 | — | — | EP | disclosed |
| EP-2602623-A2 | Mehtod for the detection of intracellular truncated receptors | Nestec S.A. (CH) | 2013-06-12 | — | — | EP | disclosed |
| US-20130045880-A1 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS | PROMETHEUS LABORATORIES INC. (US) | 2013-02-21 | — | — | US | disclosed |
| EP-2250498-B1 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS | PROMETHEUS LAB INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8163499-B2 | Drug selection for breast cancer therapy using antibody-based arrays | PROMETHEUS LABORATORIES INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110014120-A1 | TRIFUNCTIONAL IMAGING AGENT FOR MONOCLONAL ANTIBODY TUMOR-TARGETED IMAGING | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-01-20 | — | — | US | disclosed |
| EP-2250498-A1 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS | Prometheus Laboratories Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100167945-A1 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS | PROMETHEUS LABORATORIES, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| WO-2009108637-A1 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS | PROMETHEUS LABORATORIES, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090081156-A1 | Bioactive molecular matrix and methods of use in the treatment of disease | ADJUMATRIX, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2008019018-A2 | BIOACTIVE MOLECULAR MATRIX AND METHODS OF USE IN THE TREATMENT OF DISEASE | SOO HOO WILLIAM (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014120-A1 | TRIFUNCTIONAL IMAGING AGENT FOR MONOCLONAL ANTIBODY TUMOR-TARGETED IMAGING | CD47, FCGRT, FCGR3B | PTGS1 4137/4885PTGS2 4182/4885PTGER4 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.